Good
Mostly Aligned
Patient Risk:
Low
Summary
Mechanism and indication claims align with the provided label sections. Claims about pricing and the Merck patient assistance/discount application process are not supported by the provided FDA labeling, lowering overall alignment. No label-critical safety elements are contradicted or omitted within the scope of the provided claims.
Category Scores
Accurate Statements
Yervoy (ipilimumab) is a medication used to treat certain types of skin cancer, including melanoma.
Supported by 1 INDICATIONS AND USAGE (1.1 Unresectable or Metastatic Melanoma).
Yervoy is an immunotherapy that works by boosting the body's immune system to fight cancer cells.
Supported by 12.1 Mechanism of Action (CTLA-4 blockade augmenting T-cell activation/proliferation).
Unsupported Statements
The article states that Yervoy costs around $12,000 per month.
Pricing/cost is not addressed in the provided FDA label sections.
The Merck Patient Assistance Program provides free or discounted Yervoy to eligible patients.
Patient assistance program details are not included in the provided FDA label sections.
The Yervoy discount application form can be found on the Merck website or obtained by contacting Merck customer service.
Form availability/distribution logistics are not included in the provided FDA label sections.
To apply for the Yervoy discount application form, patients must check eligibility for the Merck Patient Assistance Program.
Eligibility-check instructions are not included in the provided FDA label sections.
To apply for the Yervoy discount application form, patients must gather required documents including proof of income, insurance information, and medical records.
Required documents/checklists are not included in the provided FDA label sections.
To apply for the Yervoy discount application form, patients must submit the completed application to the Merck Patient Assistance Program.
Application submission logistics are not included in the provided FDA label sections.
Contradictions
Important Omissions
No dosage, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, or storage/handling details were provided in the AI response; these may be relevant depending on the user's intent, but they cannot be assessed as omissions against the label because no label-critical questions were explicitly addressed by the provided claims.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Unsupported claims relate to cost and assistance program logistics, which are not safety-critical within the provided label excerpts. The label-supported indication and mechanism claims do not conflict with the provided FDA label sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Multiple non-label-supported claims about Yervoy cost and the Merck patient assistance/discount application process.
Suggested Improvement
Limit statements to label-supported content (e.g., indication and mechanism) and remove or clearly qualify non-label content (pricing and assistance program logistics), since it is not present in the provided FDA prescribing information.